Cresco Labs Inc. (CRLBF) Common Equity (2019 - 2026)

Cresco Labs (CRLBF) has reported Common Equity for 8 consecutive years, with $263.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 27.03% year-over-year to $263.3 million; the trailing twelve-month figure through Jun 2026 stood at $263.3 million (down 27.03% YoY), and the FY2025 full-year result was $252.5 million, down 34.95% from the prior year.
• Common Equity grew to $263.3 million in Q2 2026 per CRLBF's latest filing, from $244.2 million in the prior quarter.
• Across five years, Common Equity topped out at $783.6 million in Q2 2022 and bottomed at $244.2 million in Q1 2026.
• Historically, Common Equity has averaged $458.9 million across 5 years, with a median of $404.1 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Common Equity grew 8.31% in 2022, then tumbled 44.8% in 2023.
• Over 5 years, Common Equity stood at $587.7 million in 2022, then retreated by 27.16% to $428.1 million in 2023, then slipped by 9.32% to $388.2 million in 2024, then slumped by 34.95% to $252.5 million in 2025, then grew by 4.3% to $263.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $263.3 million, $244.2 million, and $252.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.